The immunotherapy developer, which is majority owned by BGI Group, has secured $17.8m in a GF Securities-led round that will fund clinical work on its lead product candidate.
GenoImmune, a China-based immunotherapy developer spun off by genetic testing services provider BGI Group, has raised RMB120m ($17.9m) in series A funding, according to a WeChat post from the company.
The round was led by GF Xinde Investment Management, a private equity affiliate of brokerage firm GF Securities. Huada Gene currently holds a 71.6% stake in the company according to China Money Network, which cited information from data provider Tianyancha.
Founded in 2011, GenoImmune is developing immunotherapies that are designed…
